Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Kronos Bio, Inc. (KRON)
Company Research
Source: Yahoo! Finance
— KB-0742 continues to show dose linear pharmacokinetics up to 80mg three-days-on, four-days-off dose, including increased target engagement at the 80mg vs. 60mg doses — — The escalation cohort at 80mg four-days-on, three-days-off is currently enrolling, and the expansion cohort at this dose is expected to begin enrollment in the third quarter of 2024 — SAN MATEO, Calif. and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the presentation of new data from its ongoing Phase 1/2 study, KB-0742-1001, a first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma, in a poster session at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting being held from May 31 – June 4, 2024 in Chica
Show less
Read more
Impact Snapshot
Event Time:
KRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRON alerts
High impacting Kronos Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRON
News
- Shareholders May Be More Conservative With Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For Now [Yahoo! Finance]Yahoo! Finance
- Insider Spends US$3.1m Buying More Shares In Kronos Bio [Yahoo! Finance]Yahoo! Finance
- Here's Why We're Watching Kronos Bio's (NASDAQ:KRON) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events [Yahoo! Finance]Yahoo! Finance
KRON
Earnings
- 5/9/24 - Miss
KRON
Sec Filings
- 6/12/24 - Form SC
- 6/12/24 - Form 4
- 6/4/24 - Form 4
- KRON's page on the SEC website